Age-Related Macular Degeneration (AMD) Market is expected to reach $15.7 billion by 2034

Age-related macular degeneration (AMD) is a progressive eye disease and the leading cause of irreversible vision loss among individuals aged 50 and older. It primarily affects the macula, the central part of the retina, impairing sharp central vision necessary for reading, driving, and daily tasks. As populations age and life expectancy increases, AMD has become a major global health concern with significant implications for patient independence and healthcare systems.

Download Full PDF Sample Copy of Market Report @ https://exactitudeconsultancy.com/request-sample/72217

The AMD market is evolving rapidly, driven by the rising prevalence of the disease, increased awareness of early detection, and advances in therapeutic options such as anti-VEGF drugs, gene therapy, and regenerative medicine. With a growing focus on precision medicine and long-term disease management, the AMD market presents both significant opportunities and challenges for stakeholders.

Market Overview
According to Exactitude Consultancy, the global Age-Related Macular Degeneration Market was valued at USD 8.4 billion in 2024 and is projected to reach USD 15.7 billion by 2034, growing at a CAGR of 6.5% between 2024 and 2034.

Key Highlights
• Rising prevalence: Increasing elderly populations worldwide are fueling the AMD patient pool.
• Drivers: Growing demand for anti-VEGF therapies, innovations in gene and stem-cell therapy, and expanding diagnostic capabilities.
• Challenges: High treatment costs, limited access in developing economies, and adherence challenges due to frequent treatment regimens.
• Leading players: Roche, Novartis, Regeneron, Bayer, and Apellis Pharmaceuticals dominate the market with strong therapeutic portfolios.

Segmentation Analysis
The AMD market can be segmented by type, therapy, route of administration, end-use, and region.

By Type
• Dry AMD
• Wet AMD

By Therapy
• Anti-VEGF therapy
• Photodynamic therapy
• Gene therapy
• Stem cell therapy
• Nutritional supplements and others

By Route of Administration
• Intravitreal injections
• Oral
• Others

By End Use
• Hospitals
• Specialty clinics
• Homecare settings

Segmentation Summary
Wet AMD accounts for the largest market share due to its rapid progression and the widespread use of anti-VEGF therapies such as ranibizumab and aflibercept. However, dry AMD represents a significant unmet need, as it has fewer treatment options but a much larger patient base. Emerging gene therapies and regenerative treatments are expected to reshape the treatment landscape over the next decade.

Explore Full Report here: https://exactitudeconsultancy.com/reports/72217/age-related-macular-degeneration-market

Regional Analysis
North America
• Largest regional market, driven by high disease prevalence, advanced diagnostic infrastructure, and strong presence of leading pharmaceutical companies.
• The U.S. leads adoption with widespread use of anti-VEGF therapies and robust clinical trial activity.
Europe
• Strong adoption in Germany, the U.K., and France.
• Government-backed awareness campaigns and reimbursement systems support early detection and treatment.
Asia-Pacific
• Expected to record the fastest growth between 2025 and 2034.
• Rising elderly populations in China and Japan, increasing healthcare investments, and growing access to advanced therapies fuel regional expansion.
Middle East & Africa
• Moderate growth, with GCC countries investing in ophthalmology centers and diagnostic technologies.
• Limited access and affordability issues remain challenges in African countries.
Latin America
• Brazil and Mexico dominate the regional market.
• Expanding private healthcare infrastructure and increasing awareness of AMD drive adoption.
Regional Summary
While North America holds the largest share, Asia-Pacific is projected to grow the fastest, supported by demographic trends and greater access to novel therapies.

Market Dynamics
Key Growth Drivers
1. Rising global prevalence of AMD - Increasing life expectancy and growing elderly populations are directly driving demand.
2. Innovation in therapies - Anti-VEGF biologics, gene therapies, and stem cell approaches are transforming AMD management.
3. Advances in diagnostics - Optical coherence tomography (OCT) and AI-driven retinal imaging enable earlier and more accurate detection.
4. Public health initiatives - Government-led awareness programs encourage screening and treatment compliance.

Key Challenges
1. High treatment costs - Anti-VEGF therapies require frequent intravitreal injections, making long-term treatment expensive.
2. Limited access in developing regions - Many patients in low-income countries remain undiagnosed and untreated.
3. Patient adherence - Frequent clinic visits for injections lead to compliance challenges.

Latest Trends
• Long-acting anti-VEGF drugs: New formulations aim to reduce injection frequency and improve adherence.
• Gene therapy and regenerative medicine: Offering the potential for one-time or long-lasting solutions.
• AI and digital ophthalmology: AI-based imaging platforms are aiding early diagnosis and treatment planning.
• Combination therapies: Research into combining anti-VEGF with anti-complement inhibitors to improve outcomes.

Get Your Exclusive Offer with up to 10% Discount : https://exactitudeconsultancy.com/checkout/?currency=USD&type=single_user_license&report_id=72217

Competitor Analysis
Major Players in the AMD Market
• Roche Holding AG
• Novartis AG
• Regeneron Pharmaceuticals, Inc.
• Bayer AG
• Apellis Pharmaceuticals, Inc.
• Allergan (AbbVie Inc.)
• Kodiak Sciences Inc.
• Lineage Cell Therapeutics Inc.
• Gyroscope Therapeutics Ltd.
• Iveric Bio (an Astellas company)

Competitive Dynamics
Roche, Novartis, and Regeneron dominate the market with blockbuster anti-VEGF drugs such as Lucentis, Eylea, and Vabysmo. Bayer partners with Regeneron in Europe, while Apellis has emerged as a strong contender with novel complement inhibitors. Startups and biotech firms like Kodiak Sciences and Lineage Cell Therapeutics are pushing innovation in long-acting biologics and regenerative therapies. Strategic collaborations, licensing agreements, and clinical trial expansions define the competitive landscape.

Conclusion
The Age-Related Macular Degeneration Market is set for robust growth, with the market size expected to increase from USD 8.4 billion in 2024 to USD 15.7 billion by 2034, at a CAGR of 6.5%.

Key opportunities include:
• Developing long-acting and more affordable anti-VEGF therapies.
• Expanding gene and stem cell therapies for dry AMD.
• Leveraging AI-driven diagnostics to enable earlier detection.
• Increasing access in emerging economies with cost-effective solutions.

Despite challenges such as high treatment costs and limited access, the market outlook remains highly positive. The convergence of demographic changes, technological innovation, and new therapeutic pathways ensures that the AMD market will remain a priority for healthcare providers, researchers, and pharmaceutical companies alike.

In conclusion, the Age-Related Macular Degeneration Market is entering a transformative decade where innovation and patient-centered solutions will define progress, improving quality of life for millions of patients worldwide.

This report is also available in the following languages : Japanese (加齢黄斑変性市場), Korean (연령 관련 황반변성 시장), Chinese (老年性黄斑变性市场), French (Marché de la dégénérescence maculaire liée à l'âge), German (Markt für altersbedingte Makuladegeneration), and Italian (Mercato della degenerazione maculare legata all'età), etc.

Request for a sample of this research report at (Use Corporate Mail ID for Quick Response) @ https://exactitudeconsultancy.com/reports/72217/age-related-macular-degeneration-market#request-a-sample

Our More Reports:

AI in Mental Health Market
https://exactitudeconsultancy.com/reports/73679/ai-in-mental-health-market

Telestroke Services Market
https://exactitudeconsultancy.com/reports/73680/telestroke-services-market

Behavioral Healthcare Software Market
https://exactitudeconsultancy.com/reports/73681/behavioral-healthcare-software-market

About Us
Exactitude Consultancy is a market research & consulting services firm which helps its client to address their most pressing strategic and business challenges. Our market research helps clients to address critical business challenges and also helps make optimized business decisions with our fact-based research insights, market intelligence, and accurate data.
https://bulletin.exactitudeconsultancy.com/

https://www.thehealthanalytics.com/

https://www.analytica.global/

https://www.marketintelligencedata.com/

https://www.marketinsightsreports.com/

https://exactitudeconsultancy.com/

Connect Us:
Irfan Tamboli
PHONE NUMBER +1 (704) 266-3234
EMAIL ADDRESS: sales@exactitudeconsultancy.com

This release was published on openPR.